Prosecution Insights
Last updated: November 12, 2026

Zevra Therapeutics Inc.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Analysis

Zevra Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners across 2 art units, so the portfolio follows separate examination paths.

AULAKH, CHARANJIT is the busiest examiner with 1 pending action. Counsel should prepare matter-specific responses while coordinating terminology and support for the pharmaceutical claim set.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (50%)
0
Medium (0%)
1
Easy (50%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting only1 (50%)
Multi-statute (no §101)1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
AULAKH, CHARANJIT 1 80.8% -14.4%
SEAMAN, D MARGARET M 1 76.7% +8.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18787677 LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM AULAKH, CHARANJIT —

Top Art Units

Art UnitApps
1621 1
1625 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18787677 LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM AULAKH, CHARANJIT 1621 §102§112 Non-Final OA — Pending Jul 29, 2024
18355983 KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM SEAMAN, D MARGARET M 1625 DP Final Rejection — Pending Jul 20, 2023

Managing Zevra Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Zevra Therapeutics Inc. have?

Zevra Therapeutics Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Zevra Therapeutics Inc. applications?

Charanjit Aulakh has the most, with 1 of Zevra Therapeutics Inc.'s pending office actions.

What technology area are Zevra Therapeutics Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month